Drug Store News on Sunday caught up with Brian McNamara, region head of Europe and the Americas of the recently christened GSK Consumer Healthcare, representing the joint venture between GlaxoSmithKline and Novartis to talk about what a consolidating OTC market means for the industry, and how GSK will be coming to market.
Five macro trends impacted sales of OTC medicines in 2014, Bob Sanders, EVP at IRI, shared with attendees of the Consumer Healthcare Products Association Annual Executive Conference in March. On the plus side, switch continues to drive considerable growth across OTC aisles — Rx-to-OTC accounted for 19% of OTC sales and 27% of growth in the past five years, and that trend is likely to continue, Sanders said
There was a $1.1 billion gain in OTC sales between 2013 and 2014, according to data culled from IRI, some $500 million of which can be attributed to an increase in sales across all cough-cold/allergy/sinus products and an approximate $300 million to a rise in digestive sales.
The Centers for Disease Control and Prevention acknowledged early on in the 2014-15 season that this year’s flu shot didn’t match up well with this year’s predominant H3N2 flu virus, which set the stage for a strong season. Annual sales of cough, cold and flu remedies were on the rise for the first two months of the season.
The National Advertising Division on Wednesday determined that Chattem can support certain advertising claims for “Nasacort Allergy 24HR,” an over-the-counter allergy relief medication. The claims were challenged by Merck Consumer Care.
There’s a lot happening in the allergy space right now. Chattem’s Nasacort Allergy 24HR recently hit store shelves, and in a little more than 10 weeks on the shelf the nasal corticosteroid has already generated $33.6 million in sales across total U.S. multi-outlets, according to IRI.
Retailers were preparing for the imminent launch of Chattem’s Nasacort Allergy 24HR nasal spray (triamcinolone intranasal) last month, clearing out quite a bit of shelf space for the new allergy remedy.
Sanofi and its U.S. consumer healthcare division Chattem on Tuesday announced that Nasacort Allergy 24HR Nasal Spray is now available over the counter in the United States to relieve seasonal and year-round nasal allergy symptoms, including nasal congestion, in adults and children 2 years of age and older.
Chattem recently announced that the Food and Drug Administration approved Nasacort Allergy 24HR nasal spray (triamcinolone intranasal) as an over-the-counter treatment for seasonal and year-round nasal allergies. And that means by spring 2014, there will be another allergy powerhouse alongside Allegra, Claritin and Zyrtec.
Allergy sufferers will have a new treatment option available to them by the spring allergy season. Sanofi on Friday announced that the Food and Drug Administration approved Nasacort Allergy 24HR nasal spray (triamcinolone intranasal) as an over-the-counter treatment for seasonal and year-round nasal allergies in adults and children 2 years of age and older.